PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data

Area of Science:

• Oncology
• Cancer Biology
• Immunology

Background:

• Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are effective in various cancers by inducing DNA damage, especially in tumors with DNA repair defects.
• Head and neck squamous cell carcinoma (HNSCC) exhibits aberrant DNA repair pathways, contributing to disease pathogenesis and treatment resistance.
• Cisplatin resistance is a major challenge in HNSCC treatment, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

• To review the current data supporting the integration of PARP inhibitors into HNSCC treatment strategies.
• To explore the potential of PARPi in modulating cisplatin sensitivity and enhancing anti-tumor immunity in HNSCC.
• To discuss the rationale for combining PARPi with PD-1 checkpoint inhibitors in HNSCC.

Main Methods:

• Literature review of studies investigating PARP inhibitors in cancer treatment.
• Analysis of research on DNA repair mechanisms in HNSCC.
• Examination of the immunomodulatory effects of PARPi and PD-1 inhibitors.

Main Results:

• PARPi induce DNA damage and enhance immune priming, leading to increased PD-L1 expression.
• PARPi show potential in overcoming cisplatin resistance in HNSCC.
• The combination of PARPi and PD-1 inhibitors presents a rational approach for HNSCC therapy.

Conclusions:

• PARP inhibitors represent a valuable addition to the HNSCC therapeutic armamentarium.
• Combining PARPi with PD-1 inhibitors is a promising strategy to improve treatment outcomes in HNSCC.
• Further clinical trials are warranted to evaluate the efficacy of PARPi-based combinations in HNSCC.